Skip to main content

Dr. Casey F. Jeffreys, M.D.

Neurology (Neurology Physician)

  • Medicare participating

At a glance

Years since graduation
12
In the NPI registry since
2014
Medicare patients seen, 2024
427

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2014Medical school: University of North Carolina at Chapel Hill School of Medicine
  • 2014Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology Physician primary
    NC license 2018-00730

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Neurology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
427
Services billed
51,361
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, ocrelizumab, 1 mg9,30013
Injection, natalizumab, 1 mg8,70017
Injection, gadobutrol, 0.1 ml4,20044
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg1,97013
Established patient office or other outpatient visit, 30-39 minutes149113
Injection, methylprednisolone sodium succinate, up to 125 mg12220
Established patient office or other outpatient visit, 40-54 minutes8365
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less5844
New patient office or other outpatient visit, 45-59 minutes5252
Administration of chemotherapy into vein, 1 hour or less5137

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 30 companies reported 190 payments worth $13,318 in total to this clinician.

By type
Consulting Fee$9,400
Food and Beverage$3,918

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 7, 2025EMD Serono, Inc.
Jan 7, 2025
Consulting Fee
Mavenclad · Neurology
Company’s descriptionAdvisory Board Participation (Fee For Service)
$7,200
Jun 13, 2025Novartis Pharmaceuticals Corporation
Jun 13, 2025
Consulting Fee
KESIMPTA · Neurology
$2,200

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $787,355 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
    Novartis Pharmaceuticals Corporation
  • A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
    Novartis Pharmaceuticals Corporation
  • A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse
    Novartis Pharmaceuticals Corporation
  • A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, F…
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Raleigh

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 1, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1619395092. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.